Health News Stories

Excerpts of Key Health News Stories in Major Media

Below are key excerpts of revealing news articles on health from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

The pharmaceutical industry is beginning to reap a windfall from a surprisingly lucrative niche market: drugs for poor people. The windfall, which by some estimates could be $2 billion or more this year, is a result of the transfer of millions of low-income people into the new Medicare Part D drug program that went into effect in January. Under that program...the prices paid by insurers, and eventually the taxpayer, for the medications given to those transferred are likely to be higher than what was paid under the federal-state Medicaid programs. Analysts expect it to generate hundreds of millions of additional dollars this year for the drug companies. Drugs tend to be cheaper under the Medicaid programs because the states are the buyers and by law they receive the lowest available prices for drugs. But in creating the federal Part D program, Congress -- in what critics saw as a sop to the drug industry -- barred the government from having a negotiating role. The windfall for the drug makers was made possible by a provision of the 2003 Medicare law that exempts Part D drugs from "best price" rebates that the drug makers have been required to give to the state Medicaid programs. Those rebates are meant to make sure that state Medicaid agencies pay no more than the best prices drug companies offer to any big commercial insurer. Now, under Part D, all sorts of price deals will be negotiated by dozens of Medicare drug plans. The prices will be reported to Medicare, but under a provision of the law pushed by industry lobbyists, they will otherwise be kept secret.

For the second time in two months, The Journal of the American Medical Association says it was misled by researchers who failed to reveal financial ties to drug companies. The latest incident, disclosed in letters to the editor and a correction in Wednesday's journal, involves a study showing that pregnant women who stop taking antidepressants risk slipping back into depression. Most of the 13 authors have financial ties to drug companies including antidepressant makers, but only two of them revealed their ties when the study was published in February.

Note: To understand how the drug companies manipulate results and even exert tremendous influence over the U.S. Congress, see http://www.WantToKnow.info/healthcoverup

For years the life science companies...have argued that genetically modified food is the next great scientific and technological revolution in agriculture. Nongovernmental organizations...have been cast as the villains in this unfolding agricultural drama...accused of continually blocking scientific and technological progress because of...opposition to genetically modified food. Now, in an ironic twist, new, cutting-edge technologies have made gene splicing and transgenic crops obsolete. The new frontier is called genomics, and the new agricultural technology is called marker-assisted selection, or MAS. This technology offers a sophisticated method to greatly accelerate classical breeding. A growing number of scientists believe that MAS...will eventually replace genetically modified food. Environmental organizations that have long opposed genetically modified crops are guardedly supportive of MAS technology. Rapidly accumulating information about crop genomes is allowing scientists to [use] MAS to locate desired traits in other varieties of a particular food crop, or its relatives that grow in the wild. Then they cross-breed those related plants with the existing commercial varieties to improve the crop. With MAS, the breeding of new varieties always remain within a species, thus greatly reducing the risk of environmental harm and potential adverse health effects associated with genetically modified crops. If properly used as part of a much larger systemic and holistic approach to sustainable agricultural development, MAS technology could be the right technology at the right time in history.

Note: For astonishing information on the dangers to your health of genetically modified foods, see the most popular document on our website in recent months at http://www.WantToKnow.info/deception10pg

Northfield Lab's experimental blood substitute Polyheme is currently in randomized phase III clinical trials recruiting patients without informed consent all over the country. At one point, it was being tested in as many as 27 cities; it is still being tested in 23 hospitals in 20 cities. With the FDA's approval, Northfield Lab has recruited hospitals to participate in the trial study with exemption from informed consent requirements on study participants. Although Northfield Lab claims that extensive information on the study has been made public, a vast majority of the general public has never heard of the trial.

Federal health authorities have signed a two-year deal to help states buy more than half a billion dollars worth of the antiviral drug Tamiflu as a hedge against a pandemic of deadly avian influenza, but there is a catch: States will have to pay for three-quarters of it. Under terms of the deal negotiated with Roche by the Department of Health and Human Services, the states can order up to 31 million packets of Tamiflu -- each containing a 10-pill course of treatment -- for a total cost of $596 million over the next two years. The Bush administration announced late Friday that it had contracted with Swiss drugmaker Roche Laboratories Inc. to supply Tamiflu for stockpiles in all 50 states. The federal government, meanwhile, plans to build its own centralized stockpile. The plan is to have enough antiviral drug in state and federal warehouses by December 2008 to treat 81 million people. Tamiflu is considered by scientists to be the first line of defense against the H5N1 strain of bird flu. The disease is currently confined primarily to chickens, ducks and some wild waterfowl, but researchers fear it could mutate into a form that spreads easily among humans.

Note: No mention is made here that Donald Rumsfeld has already made millions from sales of Tamiflu, and that he was on the board of the company that developed the drug. Many top researchers also believe there is little chance of avian flu mutating. Why are we spending hundreds of millions of dollars to combat a virus which has not even mutated yet? To verify these and other vital facts, see http://www.WantToKnow.info/avianflu

A 15-month inquiry by a top House Democrat has found that enforcement of the nation's food and drug laws declined sharply during the first five years of the Bush administration. For instance, the investigation found, the number of warning letters that the Food and Drug Administration issued to drug companies, medical device makers and others dropped 54 percent, to 535 in 2005 from 1,154 in 2000. The seizure of mislabeled, defective or dangerous products dipped 44 percent. The research found no evidence that such declines could be attributed to increased compliance with regulations. Investigators at the F.D.A. continued to uncover about the same number of problems at drug and device companies as before...but top officials of the agency increasingly overruled the investigators' enforcement recommendations. The investigation found that by almost every measure, enforcement actions had significantly declined from 2000 to 2005. Dr. Sidney M. Wolfe, director of the Health Research Group at the watchdog organization Public Citizen, noted that the agency now received about $380 million a year in fees from drug makers. "The public," Dr. Wolfe said, "is getting the kind of F.D.A. that the industry is paying for them to get."

Note: For lots more on collusion between government and the medical industry, see our Health Information Center at http://www.WantToKnow.info/healthinformation

At a congressional hearing, Sen. Barbara Boxer (D-Calif.) said the Environmental Protection Agency had designated as confidential the details of about 140 Superfund sites where toxic exposure remained uncontrolled. The secret data included information about how much money and time it would take to clean up the dangerous sites, including one site where the EPA predicted it would take 26 years to close off access to toxics. "This isn't a question of left or right," Boxer said, waving a document marked "Privileged" by EPA officials to prevent its release to the public. "This is a question of right and wrong." The Superfund program was created almost three decades ago in response to environmental disasters such as Love Canal, a neighborhood in Niagara Falls, N.Y., where chemical contamination forced the removal of 800 families and led to $200 million in remediation costs. Those sites are areas where the public still faces some possible exposure to toxic substances -- such as a building near buried radioactive waste that was not surrounded by a fence. A skateboard park built over the site, however, was protected by a layer of dirt. One Republican-sponsored bill moving through Congress would limit data available on toxic substances released into communities, and the U.S. Army Corps of Engineers has blocked information on flooding dangers in Florida.

Note: Major toxic hazards would seem to be a direct threat to the security of those living around the hazards, yet the EPA is keeping these records secret. If you read the entire article, you will see how the LA Times is framing this as a Democrat vs. Republican issue, when it is in fact about public health and safety.

With waived-consent studies becoming more prevalent, critics question whether the public understands how they work and whether test subjects get adequate protection. [A] trial, which is reported in today's Journal of the American Medical Association (JAMA), was halted because a device called the AutoPulse, which was used to revive cardiac-arrest victims, failed to save more lives than when rescuers performed cardiopulmonary resuscitation. Patients in these types of studies...are treated under a broad federal rule that allows researchers to test emergency treatments on patients with specific, life-threatening medical conditions without their explicit consent as long as they remain under close watch of independent reviewers. Studies have included large, multi-city, randomized trials, which scientists consider the gold standard for medical research. The [PolyHeme] trial has raised concern among some ethicists and alarm in Congress, where Sen. Charles Grassley, R-Iowa, chairman of the Finance Committee, is conducting an investigation. Grassley is concerned that people who live in the 19 states where PolyHeme is being tested have had inadequate notice about the trial. The FDA requires that community input be sought in the regions around test sites. "It is outrageous that, for all intents and purposes, the FDA allowed a clinical trial to proceed, which makes every citizen in the United States a potential 'guinea pig,' without providing a practical, informative warning to the public," Grassley wrote in a letter to the FDA in February.

In a public health emergency, suspected victims would no longer have to give permission before experimental tests could be run to determine why they're sick, under a federal rule published Wednesday. Privacy experts called the exception unnecessary, ripe for abuse and an override of state informed-consent laws. Health care workers will be free to run experimental tests on blood and other samples taken from people who have fallen sick as a result of a bioterrorist attack, bird flu outbreak, detonation of a dirty bomb or any other life-threatening public health emergency, according to the rule issued by the Food and Drug Administration. The rule took effect Wednesday but remains subject to public comment until Aug. 7. The FDA said it published the rule without first seeking comments because it would hinder the response to an outbreak of bird flu or other public health emergency.

A lawsuit filed Wednesday seeks to force the U.S. government to conduct mandatory reviews of genetically engineered foods and require labeling of such foods once they are approved. The Center for Food Safety's suit against the Food and Drug Administration comes after years of lobbying by environmental and consumer groups for more stringent regulation and labeling of biotech crops. Genetically modified crops, such as soybeans, corn, and canola, are grown widely throughout the United States, and the world leader in development and marketing of the gene-altered crops is...Monsanto. Yet the United States requires no independent testing of these crops or the food products they are used in, does not mandate what data companies must submit for review, and does not require that foods that contain biotech crops be labeled. CFS and more than fifty consumer and environmental groups, filed a legal petition with the FDA in March 2000, asking the agency to adopt a more rigorous approach to biotech food regulation, but the CFS said Wednesday that the FDA had ignored the petition. At various times over the last several years, different scientists, including some within the FDA, have warned that altering the genetic makeup of a food plant by inserting genes from one organism into another...could trigger unexpected food allergies, create toxins in food, or spread antibiotic-resistant disease. CFS said the tests that exposed that potential hazard have not been conducted on any of the genetically modified foods currently marketed.

Note: Many laboratory animals died in scientific tests of GM foods, yet this news has yet to be reported in the major media. If you want to understand the risks involved with the ever-increasing numbers of genetically modified organisms in the food you eat, don't miss: http://www.WantToKnow.info/deception10pg

American researchers say that their study supports the findings of Andrew Wakefield, the discredited gastroenterologist who raised fears that the measles, mumps and rubella injection might be causing autism. His research, published in The Lancet in 1998, detected traces of the measles virus in the guts of 12 children with autism. The latest study, led by Arthur Krigsman, of New York University School of Medicine, involved 275 children. Serious intestinal inflammations were found in some of the autistic children and biopsies of gut tissue were performed on 82 of them. Of these, 70 are said to have shown evidence of the measles virus, which so far has been confirmed in 14 cases by more stringent DNA tests. Steve Walker, assistant professor at Wake Forest University Medical Centre, North Carolina, who analysed the gut samples, said the work mirrored Dr Wakefield's study. All the children involved were diagnosed with autism and had come to Dr Krigsman and Dr Walker seeking help for symptoms of serious digestive problems for which no explanation could be found. Mainstream science has repeatedly examined the theory of a link between MMR and autism and found no evidence to back it.

Note: Though "mainstream science" has allegedly found no links, many other scientific and media sources have found strong evidence of a link. See http://www.WantToKnow.info/060215vaccinesmercurydangers

The American Diabetes Association...privately enlisted an Eli Lilly & Co. executive to chart its growth strategy. The National Alliance on Mental Illness...lobbies for treatment programs that also benefit its drug-company donors. The National Gaucher Foundation...gets nearly all its revenue from one drugmaker, Genzyme Corp. Many patient groups and drug companies maintain close, multimillion-dollar relationships while disclosing limited or no details about the ties. An Inquirer examination of six groups, each a leading advocate for patients in a disease area, found that the groups rarely disclose such ties when commenting or lobbying about donors' drugs. Combined, the six received at least $29 million from drug companies last year. The amount ranged from 2 percent to 7 percent of revenue at the Arthritis Foundation, to 89 percent to 91 percent at the much smaller National Gaucher Foundation. The funding usually comes from the companies' marketing or sales divisions, not charity offices. Grants often rise with promotional spending as a drug hits the market and fall when sales ebb. Donations from Merck and Pfizer Inc. to the Arthritis Foundation more than doubled, to at least $1.65 million combined, in 2000 as they launched Vioxx and Celebrex. Merck explicitly wove the foundation into sales strategies. In 2000-2001, the American Diabetes Association did not disclose an unusual gift from Lilly: a lent executive, Emerson "Randy" Hall Jr., who moved into its Alexandria, Va., headquarters and coached it on growth strategies, all paid by Lilly.

Note: If you want to understand how the huge pharmaceutical industry influences what you know about their drugs, this article is a must read. You may first want to read a riveting two-page summary of an exposé by the former editor-in-chief of the New England Journal of Medicine, who details major collusion and corruption in the pharmaceutical industry at http://www.WantToKnow.info/healthcoverup

Drug companies fund a growing number of the studies in leading psychiatric journals, and drugs fare much better in these company-funded studies than in trials done independently or by competitors, researchers reported Wednesday. About 57% of published studies were paid for by drug companies in 2002, compared with 25% in 1992, says psychiatrist Igor Galynker of Beth Israel Medical Center in New York City. His team looked at clinical research in four influential journals: American Journal of Psychiatry, Archives of General Psychiatry, Journal of Clinical Psychiatry and Journal of Clinical Psychopharmacology. In the report, released at the American Psychiatric Association meeting in Toronto, reviewers did not know who paid for the studies they evaluated, Galynker says. There were favorable outcomes for a medication in about: eight out of 10 studies paid for by the company that makes the drug; five out of 10 studies done with no industry support; three out of 10 studies done by competitors of the firm making the drug. As drug companies increasingly fund research that yields favorable outcomes for their drugs, there may be a built-in bias because journals are reluctant to publish studies with negative or inconclusive findings.

Note: To learn more about the astonishing profits and power of the major drug companies, read our concise summary of a major insider's research at http://www.WantToKnow.info/healthcoverup

It's a quiet mountain community, but some residents claim something's happening in the sky that's making them sick. Mystery clouds and unusual contrails ... Is it a weather experiment on a massive scale? In a Channel 4 News investigation, Paul Moyer looks into why some say the government is manipulating the weather. Watch: Video Report. References: U.S. Senate Committee testimony on Weather Modification, Owning the Weather in 2025 (U.S. Airforce), California Skywatch (Rosalind Peterson), Alpenhorn News Stories.

Note: In certain circles, the phenomenon of chemtrails is hotly debated. Very rarely does it make the news. The fact that NBC in LA is reporting on this is big. Don't miss the video news report available free online at: http://www.nbc4.tv/video/9265818/detail.html.

White blood cells from mice that are naturally immune to cancer cured tumors in other mice and provided them with lifelong immunity to the disease, researchers reported Monday. The finding indicates the existence of a biological pathway previously unsuspected in any species. A small team of researchers is working to understand the genetic and immunological basis of the surprising phenomenon. Preliminary studies hint at the existence of a similar resistance in humans. Researchers hope that harnessing the biological process could lead to a new approach to treating cancer. But Dr. Zhen Cui of Wake Forest, whose team published the findings in the Proceedings of the National Academy of Science, said he expected rapid replication of the results because the findings were so clear-cut and easily observed. "This is a truly remarkable phenomenon -- and it really needs confirmation from other institutions," he said. The team took white blood cells from the immune mice ... and injected them into mice already carrying a variety of tumors, some of which were extremely aggressive. In every case, the cancers were destroyed, even if the cells were injected at a point distant from the tumor. Healthy tissues were not affected. The mice that received the cells, furthermore, were protected from new tumors for the rest of their lives. The researchers have no idea how the immunity continues.

Note: Why was this not in the headlines and not given a title like "Cancer Cure Found for Mice"? Most major papers didn't even report the story, and an article in the New York Times was titled simply "A Strain of Mice Appears Able to Resist Cancer Cells." Could it be that the power brokers in the medical industry know that a cancer cure would cause huge financial losses for them? For what happened to an incredible scientist in the past who discovered a cancer cure for humans, click here.

Vaccine industry officials helped shape legislation behind the scenes that Senate Majority Leader Bill Frist secretly amended into a bill to shield them from lawsuits, according to e-mails obtained by a public advocacy group. E-mails and documents written by a trade group for the vaccine-makers show the organization met privately with Frist's staff and the White House about measures that would give the industry protection from lawsuits filed by people hurt by the vaccines. Frist, along with House Speaker Dennis Hastert, R-Ill., ordered the vaccine liability language inserted in a defense spending bill in December without debate and in violation of usual Senate practice. In a written statement, Frist spokeswoman Amy Call stated that the senator had promised publicly to include the vaccine liability protection in the defense spending bill. She did not address the issue of the influence of industry lobbyists.

Note: For one-paragraph summaries of media articles showing why the vaccine makers want this protection, click here.

Fraudulent research regularly appears in the 30,000 scientific journals published worldwide, a former editor of the British Medical Journal (BMJ) said today. Even when journals discover that published research is fabricated or falsified they rarely retract the findings, according to Richard Smith, who was also chief executive of the BMJ publishing group. Writing in the latest edition of the Journal of the Royal Society of Medicine, Dr Smith called on editors to blow the whistle on bad research and to use their clout to pressure universities into taking action against dodgy researchers. The former BMJ editor said it was likely that research fraud was "equally common" in the 30,000 plus scientific journals across the globe but was "invariably covered up". His call for action comes in the wake of several high profile cases of fraudulent research, including the Korean scientist Hwang Woo-suk who fabricated stem cell research that it was claimed would open up new ways to treat diseases like Parkinson's. Dr Smith criticised the failure of scientific institutions, including universities, to discipline dodgy researchers even when alerted to problems by journals. "Few countries have measures in place to ensure research is carried out ethically," he said. "Most cases are not publicised. They are simply not recognised, covered up altogether or the guilty researcher is urged to retrain, move to another institution or retire from research."

Note: For reliable information on the collusion of industry, government, and research facilities who place profits above advances in public health: http://www.WantToKnow.info/healthcoverup

A sugar pill, a salt solution, a doctor in a white jacket -- these all have the power to cure as long as the patient believes in their healing qualities. That seems impossible. So what does science say about the elusive placebo effect? Very little research has been done in this area of medicine. The pharmaceutical industry can’t profit; after all, they can’t make money from sugar pills. It is often forgotten that the effect could help people and shave billions off spiralling health-care costs. If researchers could gain more insight into how the effect works, it would stand as one of the biggest medical breakthroughs in history. Some people are convinced that the effect proves that strength of mind is sufficient to heal the body. Placebos have...proven successful in treating depression, anxiety, stress, warts and ulcers -- sometimes in as many as 60 to 70 percent of the cases. There are...objective effects everyone can measure. Placebo treatments have been shown to lower blood pressure and cholesterol levels as well as improve reaction speeds, pulse rates and immune-system activity. Ultimately, the placebo phenomenon points to a strange paradox in modern medical science. As soon as an alternative-health treatment proves successful, it is dismissed as the placebo effect. It works only because people believe in it. Yet this explanation appears to contradict one of the foundations of medical science, which stresses that the mind and body are separate, therefore ruling out the possibility of healing through belief.

Note: For ideas on why the placebo effect has rarely been studied, see our two-page health cover-up summary at http://www.WantToKnow.info/healthcoverup

The World Bank has been accused of publishing false accounts and wasting money on ineffective medicines in its malaria treatment programme. A Lancet paper claims the bank faked figures, boosting the success of its malaria projects, and reneged on a pledge to invest $300-500m in Africa. It also claims the bank funded obsolete treatments - against expert advice. The claims against the bank [were] made by 13 international public health experts headed by Amir Attaran, of Canada's University of Ottawa. They quote the bank saying that it reduced deaths from malaria in the Indian states of Gujarat by 58%, Maharashtra by 98% and Rajasthan by 79%. According to India's Directorate of National Vector Borne Disease Control Programme, deaths from malaria rose in all three states in the 2002-3 period in question. "Our investigations suggest that the bank wasted money and lives on ineffective medicines." It accuses the bank of supplying India with an anti-malarial drug, called chloroquine, at a cost of $1.8m, which it says is unsuitable for the type of malaria seen there and against World Health Organisation guidelines.

Every psychiatric expert involved in writing the standard diagnostic criteria for disorders such as depression and schizophrenia has had financial ties to drug companies that sell medications for those illnesses, a new analysis has found. Of the 170 experts in all who contributed to the manual that defines disorders from personality problems to drug addiction, more than half had such ties, including 100 percent of the experts who served on work groups on mood disorders and psychotic disorders. "I don't think the public is aware of how egregious the financial ties are in the field of psychiatry," said Lisa Cosgrove, a clinical psychologist at the University of Massachusetts in Boston. The analysis comes at a time of growing debate over the rising use of medication as the primary or sole treatment for many psychiatric disorders, a trend driven in part by definitions of mental disorders in the psychiatric manual. Cosgrove said she began her research after discovering that five of six panel members studying whether certain premenstrual problems are a psychiatric disorder had ties to Eli Lilly & Co., which was seeking to market its drug Prozac to treat those symptoms. The process of defining such disorders is far from scientific, Cosgrove added: "You would be dismayed at how political the process can be."

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.